Mohammed T. Abou-Saleh

322 PRINCIPLES AND PRACTICE OF GERIATRIC PSYCHIATRYpolymerization of -amyloid peptide. Biochim Biophys Acta 1997;1360: 17–29.46. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline,-tocopherol or both as a treatment for Alzheimer’s disease. N Engl JMed 1997; 336: 1216–22.47. Stoll S, Scheuer K, Pohl O et al. Ginkgo biloba extract (Egb761)independently improves changes in passive avoidance learning in theageing mouse. Pharmacopsychiatry 1996; 29: 144–9.48. Henderson VW. The epidemiology of estrogen replacement therapyand Alzheimer’s disease. Neurology 1997; suppl 7: s27–35.49. LeBlanc ES, Janowsky J, Cha BKS et al. Hormone replacementtherapy and cognition: systematic review and meta-analysis. JAmMed Assoc 2001; 285: 1489–99.50. Fillenbaum G, Hanlon JT, Landerman LR et al. Impact of estrogenuse on decline in cognitive function in a representative sample of oldercommunity resident women. Am J Epidemiol 2001; 153: 137–44.51. Seshadri S, Zornberg GL, Derby LE et al. Postmenopausal estrogenreplacement therapy and the risk of Alzheimer’s disease. Arch Neurol2001; 58: 435–40.52. Yaffe K, Krueger K, Sarkar S et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001; 344:1207–13.53. Mudd SH, Levy HL, Skovby F. Disorders of trans-sulfuration. InScriver CP, Beaudet AL, Sly WS et al., eds., The Metabolic Basis ofInherited Disease. New York: McGraw-Hill, 1989; 693–734.54. McCully KS. Vascular pathology of homocysteinemia: implicationsfor the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111–28.55. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis.Atherosclerosis 1975; 22: 215–27.56. Selhub J, Jacques PF, Bostom AG et al. Association between plasmahomocysteine concentrations and extracranial carotid-artery stenosis.N Engl J Med 1995; 32: 286–91.57. Selhub J, Bagley LC, Miller J et al. B vitamins, homocysteine andneurocognitive function in the elderly. Am J Clin Nutr 2000; 1: s614–20.58. Selhub J, Jacques PF, Wilson PWF et al. Vitamin status and intake asprimary determinants of homocysteinemia in an elderly population. JAm Med Assoc 1993; 270: 2693–8.59. Mayer EL, Jacobson DW, Robinson K. Homocysteine and coronaryatherosclerosis. J Am Coll Cardiol 1996; 27: 517–27.60. Miller JW. Homocysteine, Alzheimer’s disease and cognitivefunction. Nutrition 2000; 16: 675–7.61. Miller JW, Green R, Allen LH et al. Homocysteine correlates withcognitive function in Sacramento Area Latino Study of Ageing(SALSA). Fed Am Soc Exp Biol 1999; 13: A374.62. Riggs KM, Spiro A, Tucker K et al. Relations of vitamin B 12 , vitaminB 6 , folate and homocysteine to cognitive performance in thenormative ageing study. Am J Clin Nutr 1996; 63: 306–14.63. Kalmijn S, Launer LJ, Lindemans J et al. Total homocysteine andcognitive decline in a community-based sample of elderly subjects.Am J Epidemiol 1999; 150: 283–9.64. Prins ND, Vermeer SE, Clarke R et al. Homocysteine and cognitivefunction in the elderly: the Rotterdam Scan Study. Neurology 2001;suppl. 3: A240–41.65. Morris MS, Jaques PF, Rosenberg IH et al. Hyperhomocysteinemiaassociated with poor recall in the third National Health and NutritionExamination Survey. Am J Clin Nutr 2001; 73: 927–33.66. Breteler MMB. Vascular risk factors for Alzheimer’s disease: anepidemiological perspective. Neurobiol Ageing 2000; 1: 153–60.67. Leblhuber F, Walli J, Artner-Dworzak E et al.Hyperhomocysteinemia in dementia. J Neur Transm 2000; 107:1469–74.68. Wang HX, Wahlin A, Basun H et al. Vitamin B 12 and folate inrelation to the development of Alzheimer’s disease. Neurology 2001;156: 1188–94.69. White AR, Huang XD, Jobling MF et al. Homocysteine potentiatescopper and amyloid peptide-mediated toxicity in primary neuronalcultures: possible risk factors in the Alzheimer’s typeneurodegenerative pathway. J Neurochem 2001; 6: 1509–20.70. Nilsson K, Warkentin S, Hultberg B et al. Treatment of cobalamindeficiency in dementia, evaluated clinically and with cerebral bloodflow measurements. Ageing Clin Exp Res 2000; 12: 199–207.71. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitivefunctions after cobalamin/folate supplementation in elderly patientswith dementia and elevated plasma homocysteine. Int J GeriatPsychiat 2001; 16: 609–14.72. Ho Pi, Collins SC, Dhitavat S et al. Homocysteine potentiates -amyloid neurotoxicity: role of oxidative stress. J Neurochem 2001; 78:249–53.73. Kivipelto M, Helkala EL, Laasko MP et al. Midlife vascular riskfactors and Alzheimer’s disease in later life: longitudinal, populationbasedstudy. Br Med J 2001; 322: 1447–51.74. Jick H, Zornberg HJ, Jick SS et al. Statins and the risk of dementia.Lancet 2000; 56: 1627–31.75. Wolozin BW, Ruosseau P, Celesia GG, Siegel G. Decreasedprevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl co-enzyme A reductase inhibitors. Arch Neurol 2000;57: 439–43.76. Simons M, Keller P, De Strooper B et al. Cholesterol depletioninhibits the generation of amyloid in hippocampal neurons. ProcNatl Acad Sci USA 1998; 95: 460–4.77. Jarvik GP, Wijsman EM, Kukull WA et al. Interactions ofapolipoprotein E genotypes, total cholesterol level, age and sex inprediction of Alzheimer’s disease: a case-control study. Neurology1995; 45: 1092–6.78. Games D, Adams D, Alessandrini R et al. Development ofneuropathology similar to Alzheimer’s disease in transgenic miceoverexpressing the 717 V-F -amyloid precursor protein. Nature 1995;373: 523–8.79. Sparks DL. Coronary artery disease, hypertension, ApoE, andcholesterol: a link to Alzheimer’s disease? Ann NY Acad Sci 1997;826: 128–46.80. Notkola IL, Sulkava R, Pekkanen J et al. Serum total cholesterol,apolipoprotein E epsilon 4 allele, and Alzheimer’s disease.Neuroepidemiology 1998; 17: 14–20.81. Refolo LM, Duff K, Malester B et al. Hypercholesterolemiaaccelerates amyloid pathology in a transgenic mouse model ofAlzheimer’s Disease. J Neuropathol Neurol 2000; 59: 20–23.82. Fassbender K, Simons M, Bergmann C et al. Simvastatinstrongly reduces levels of Alzheimer’s disease -amyloid peptidesA42 and A40 in vitro and in vivo. Proc Natl Acad Sci USA2001; 98: 5856–61.83. Glen AIM, Whalley LJ. Alzheimer’s Disease: Early Recognition ofPotentially Reversible Deficits. Edinburgh: Churchill Livingstone,1979.84. Villa A, Latasa MJ, Pasual A. Nerve growth factor modulatesthe expression and secretion of -amyloid precursor proteinthrough different mechanisms in PC12 cells. J Neurochem 2001;77: 1077–84.85. Grudnman M, Correy-Bloom J, Thal LJ. Perspectives in clinicalAlzheimer’s disease research and the development of antidementiadrugs. J Neur Transm 1998; suppl. 53: s255–75.86. Emilien G, Beyreuther K, Masters CL, Maloteaux JM. Prospects forpharmacological intervention in Alzheimer’s disease. Arch Neurol2000; 57: 454–9.87. Cacabelos R, Alvarez A, Lombardi A et al. Pharmacologicaltreatment of Alzheimer’s disease: from psychotropic drugs andcholinesterase inhibitors to pharmacogenomics. Drugs Today 2000;36: 415–99s.88. Maimone D, Dominici R, Grimaldi LME. Pharmacogenomics ofneurodegenerative disorders. Eur J Pharmacol 2001; 413: 11–29.89. Stoessl AJ. Antisense strategies for the treatment of neurologicaldisease. Expert Opin Therapeut Patents 2001; 11: 547–62.90. Wiltfang J, Esselmann H, Maler JM et al. Molecular biology ofAlzheimer’s dementia and its clinical relevance to early diagnosis andnew therapeutic strategies. Gerontology 2001; 47: 65–71.91. Selkoe D. Translating cell biology into therapeutic advances inAlzheimer’s disease. Nature 1999; 399: A23–31.92. Selkoe DJ. Alzheimer’s disease: a central role for amyloid. JNeuropathol Exp Neurol 1994; 53: 438–47.93. Jhee S, Shiovitz T, Crawford AW, Cutler NR. -amyloid therapies inAlzheimer’s disease. Expert Opin Invest Drugs 2001; 10: 593–605.94. Creemers JWM, Dominguez DI, Plets E et al. Processing of -secretase by furin and other members of the proprotein convertasefamily. J Biol Chem 2000; 276: 4211–17.95. Cherny RA, Atwood CS, Xilinas ME et al. Treatment with acopper–zinc chelator markedly and rapidly inhibits -amyloid